GET DAILY SIGNALSAdaptHealth (AHCO) Delivers Solid Q3 Results, Lifting Shares by +9.6%
Key Takeaways
- AdaptHealth reported third quarter 2026 net revenue from continuing operations of $745.6 million, up 10.9% year over year and above the roughly $726 million consensus estimate.
- Adjusted EBITDA came in at $141.9 million, ahead of the approximately $130 million consensus expectation.
- On a GAAP basis, the company posted a net loss attributable to AdaptHealth of $168.2 million, driven largely by a $184.8 million non-cash goodwill impairment charge.
- GAAP earnings per share of -$1.13 came in well below the consensus estimate of roughly -$0.06, reflecting the one-time impairment.
- Management raised its full-year revenue guidance midpoint to approximately $2.89 billion, and its adjusted EBITDA outlook landed above analyst expectations.
- Shares jumped roughly 9.6% to around $6.48 immediately following the release, signaling a favorable reaction to the operating beat despite the headline loss.
Why This Quarter Matters for AdaptHealth
AdaptHealth Corp. provides patient-centered healthcare-at-home solutions, including home medical equipment, supplies, and services in sleep, respiratory, and wellness areas. The third quarter of 2026 came at a key point in the company’s ongoing transformation, as it navigates the largest patient transition in the industry and simplifies its portfolio through the pending sale of the Diabetes Health business. From what I see, investors are focused on whether the largest capitated contract can shift from a margin pressure point to a growth driver, and whether cost controls can help offset integration costs. This report provides useful insight into organic demand, profitability trends, and the reliability of full-year guidance amid significant restructuring.
Breaking Down the Reported Numbers
AdaptHealth reported third quarter 2026 net revenue from continuing operations of $745.6 million, an increase of 10.9% from the prior-year quarter, with organic growth of 12.8%. Revenue beat the midpoint of the company’s own guidance by about $15.6 million and topped consensus estimates of roughly $726 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Sleep Health revenue rose 11% to $393.9 million, Respiratory Health revenue grew 7.8% to $190.8 million, and Wellness at Home revenue increased 14.5% to $161 million. Total capitated revenue reached $110.3 million, or about 15% of continuing operations revenue.
Adjusted EBITDA was $141.9 million, compared with $146.1 million in the prior-year quarter, for a margin of 19.0% versus 21.7% a year ago. The result exceeded consensus estimates of approximately $130 million. On a GAAP basis, the company reported a net loss attributable to AdaptHealth of $168.2 million, driven primarily by a $184.8 million non-cash goodwill impairment charge related to the decline in its equity market capitalization. This led to a GAAP EPS loss of -$1.13, below consensus, though the impairment and a related $12 million gain on the contribution of its e-commerce business were excluded from adjusted EBITDA.
Market Reaction to the Results
Investors responded positively to the operating results even with the headline GAAP loss. Shares rose roughly 9.6% to around $6.48 right after the release, reflecting attention on the revenue and adjusted EBITDA beats, the improving margin trajectory of the largest capitated contract, and the raised full-year revenue outlook. The goodwill impairment, while large on a GAAP basis, was non-cash and linked to the reduced equity market capitalization, which appeared to limit its effect on sentiment. The market’s reaction indicates that investors are placing more weight on stabilization in the core business and progress toward a more focused portfolio than on the one-time accounting charge.
Looking Ahead and Key Items to Watch
Management raised its full-year revenue guidance midpoint to approximately $2.89 billion, while its adjusted EBITDA outlook for the year came in above analyst consensus. This points to growing confidence in the core business as the company moves past a period of heavy transition work.
A key item to monitor is the pending sale of the Diabetes Health business. Closing that deal would complete a multi-year effort to focus the portfolio around Sleep Health, Respiratory Health, and Wellness at Home, and it could change both reported revenue and adjusted EBITDA comparisons in future quarters.
Investors should also follow the performance of the largest capitated contract, which improved from a negative margin in the second quarter to roughly 10% in the third quarter and was trending near 14% at the end of the period. Continued margin expansion there, along with labor and operating-expense discipline, will be important for sustaining adjusted EBITDA growth.
Finally, balance-sheet developments merit attention. The company ended the quarter with net debt of about $1.85 billion and a consolidated total leverage ratio of approximately 3.05 times. Any further debt reduction, together with cost trends and demand signals in sleep and respiratory resupply, will help show whether the momentum management describes carries into 2027.
Using Tickeron Tools in My Research
I often turn to Tickeron’s AI Screener when analyzing earnings reports like this one. It lets me quickly filter stocks and ETFs by technical patterns, fundamentals, and AI-driven signals, which helps surface comparable ideas across the healthcare space without spending hours on manual screens. The tool has become a regular part of how I cross-check sector trends and identify potential opportunities that align with the themes I see in a company’s results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AHCO's RSI Oscillator leaves overbought zone
The 10-day RSI Indicator for AHCO moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 24 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where AHCO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for AHCO turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AHCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
AHCO broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AHCO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on AHCO as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
AHCO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AHCO crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +4.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where AHCO advanced for three days, in 225 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.608) is normal, around the industry mean (4.204). P/E Ratio (-3.760) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.240) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AHCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical products for both rental and sale
Industry MedicalNursingServices
Advertisement